Gut Microbial Control of Neurotransmitters and Their Relation to Neurological Disorders: A Comprehensive Review

Abstract

The study explores the vital role of gut microbiota in regulating neurotransmitters and its subsequent effects on brain function and mental health. It aims to unravel the mechanisms by which microbial metabolites influence neurotransmitter synthesis and signaling. The ultimate goal is to identify potential therapeutic strategies targeting gut microbiota for the management and treatment of neurological disorders, such as depression, autism spectrum disorder (ASD), anxiety, and Parkinson’s disease. The review synthesizes current research on the gut-brain axis, focusing on the influence of gut microbial metabolites on key neurotransmitters, including dopamine, serotonin, and gamma-aminobutyric acid (GABA). It incorporates a multidisciplinary approach, linking microbiology, neurobiology, and clinical research. Each section presents an in-depth review of scientific studies, clinical trials, and emerging therapeutic strategies. The findings highlight the intricate interplay between gut microbiota and the central nervous system. Gut microbes significantly impact the synthesis and signaling of crucial neurotransmitters, which play a pivotal role in neurological health. Evidence supports the hypothesis that modulating gut microbiota can alter neurotransmitter output and alleviate symptoms associated with neurological disorders. Notable therapeutic potentials include microbiota-targeted interventions for managing depression, ASD, anxiety, and Parkinson's disease. This comprehensive analysis underscores the critical connection between gut microbiota and neurological health. By bridging gaps between microbiology, neurobiology, and clinical practice, the study opens avenues for innovative therapeutic approaches. It provides a valuable resource for researchers, clinicians, and students, emphasizing the need for continued investigation into gut microbiota’s role in neurological disorders and its therapeutic potential.

Keywords

gut microbiota - GABA - Parkinson's disease - neurobiology - neuroscience - neurotransmitters

Publikationsverlauf

Eingereicht: 22. Januar 2025

Angenommen nach Revision: 03. Februar 2025

Artikel online veröffentlicht:
12. März 2025

• References

• 1 Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474: 1823
• 2 Donald K, Finlay BB. Early-life interactions between the microbiota and immune system: impact on immune system development and atopic disease. Nat Rev Immunol 2023; 23: 735-748
• 3 Hay SI, Abajobir AA, Abate KH. et al. Lancet. 2017 390. 1260-1344
• 4 Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 2016; 14: 20-32
• 5 Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Human Develop 2001; 65: 21-37
• 6 Herlenius E, Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp Neurol 2004; 190: 8
• 7 Teleanu RI, Niculescu AG, Roza E. et al. Neurotransmitters – key factors in neurological and neurodegenerative disorders of the central nervous system. Int J Mol Sci 2022; 23: 5954
• 8 Forsythe P, Bienenstock J, Kunze WA. Vagal pathways for microbiome-brain-gut axis communication. Adv Exp Med Biol 2014; 817: 115-133
• 9 Qiao Y, Wu M, Feng Y. et al. Alterations of oral microbiota distinguish children with autism spectrum disorders from healthy controls. Sci Rep 2018; 8: 1-12
• 10 Kaelberer MM, Buchanan KL, Klein ME. et al. A gut-brain neural circuit for nutrient sensory transduction. Science 2018; 361: eaat5236
• 11 Huang F, Wu X. Brain neurotransmitter modulation by gut microbiota in anxiety and depression. Front Cell. Develop Biol 2021; 9: 649103
• 12 Oswal A, Cao C, Yeh CH. et al. Neural signatures of hyperdirect pathway activity in Parkinson’s disease. Nat Commun 2021; 12: 1-14
• 13 Jang SE, Lim SM, Jeong JJ. et al. Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice. Mucosal Immunol 2018; 11: 369-379
• 14 Wilson DM, Cookson MR, Van Den Bosch L. et al. Hallmarks of neurodegenerative diseases. Cell 2023; 186: 693-714
• 15 Loh JS, Mak WQ, Tan LKS. et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduc Target Ther 2024; 9: 1-53
• 16 Bellenguez C, Küçükali F, Jansen IE. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 2022; 54: 412-436
• 17 Yin Z, Herron S, Silveira S. et al. Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease. Nat Neurosci 2023; 26: 1196-1207
• 18 Gulen MF, Samson N, Keller A. et al. Nature. 2023 620. 374-380
• 19 Albrecht DS, Sagare A, Pachicano M. et al. Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain Behav Immun 2021; 94: 299
• 20 Schwarcz R, Bruno JP, Muchowski PJ. et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477
• 21 Kanova M, Kohout P. Serotonin – its synthesis and roles in the healthy and the critically Ill. Int J Mol Sci 2021; 22: 4837
• 22 Heisler LK, Chu HM, Brennan TJ. et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 1998; 95: 15049-15054
• 23 Vahid Ansari F, Daigle M, Manzini MC. et al. Abrogated Freud-1/Cc2d1a repression of 5-HT1A autoreceptors induces fluoxetine-resistant anxiety/depression-like behavior. J Neurosci 2017; 37: 11967
• 24 Santarelli L, Saxe M, Gross C. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809
• 25 Assie MB, Bardin L, Auclair AL. et al. F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 2010; 13: 1285-1298
• 26 Nautiyal KM, Tritschler L, Ahmari SE. et al. A lack of serotonin 1B autoreceptors results in decreased anxiety and depression-related behaviors. Neuropsychopharmacology 2016; 41: 2941
• 27 Tatarczyńska E, Antkiewicz-Michaluk L, Kłodzińska A. et al. Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: a possible mechanism of action. Eur J Pharmacol 2005; 516: 46-50
• 28 Chenu F, David DJP, Leroux-Nicollet I. et al. Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatr Neurosci 2008; 33: 541
• 29 Patel JG, Bartoszyk GD, Edwards E. et al. The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. Synapse 2008; 52: 73-75
• 30 Marek GJ, Martin-Ruiz R, Abo A. et al. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005; 30: 2205-2215
• 31 Diaz SL, Doly S, Narboux-Nme N. et al. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatr 2012; 17: 154-163
• 32 Li B, Zhang S, Zhang H. et al. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology 2008; 201: 443-458
• 33 Ramamoorthy R, Radhakrishnan M, Borah M. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008; 19: 29-40
• 34 Pascual-Brazo J, Castro E, Díaz Á. et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT₄ receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631-643
• 35 Lucas G, Rymar VV, Du J. et al. Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action. Neuron 2007; 55: 712-725
• 36 Kassai F, Schlumberger C, Kedves R. et al. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression. Behav Pharmacol 2012; 23: 397-406
• 37 Wesołowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007; 52: 1274-1283
• 38 Mnie-Filali O, Faure C, Lambás-Seas L. Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy. Neuropsychopharmacology 2011; 36: 1275
• 39 Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients 2021; 13: 2099
• 40 Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Archiv Biochem Biophy 2011; 508: 1-12
• 41 Hamamah S, Aghazarian A, Nazaryan A. et al. Role of microbiota-gut-brain axis in regulating dopaminergic signaling. Biomedicines 2022; 10: 436
• 42 Salamone JD, Correa M, Farrar A. et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 2007; 191: 461-482
• 43 Frank MJ. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cognit Neurosci 2005; 17: 51-72
• 44 Otaru N, Ye K, Mujezinovic D. et al. GABA production by human intestinal bacteroides spp.: prevalence, regulation, and role in acid stress tolerance. Front Microbiol 2021; 12: 656895
• 45 Madabushi JS, Khurana P, Gupta N. Gut biome and mental health: do probiotics Work?. Cureus 2023; 15: e40293
• 46 Allen MJ, Sabir S, Sharma S. GABA receptor. Trend Pharmacol Sci 2023; 2: 62-64
• 47 Fattorusso A, Di Genova L, Dell’isola GB. Autism spectrum disorders and the gut mmicrobiota. Nutrients 2019; 11: 521
• 48 Cauda F, Nani A, Costa T. et al. The morphometric co-atrophy networking of schizophrenia, autistic and obsessive spectrum disorders. Hum Brain Mapp 2018; 39: 1898-1928
• 49 Khan S, Moore RJ, Stanley D. et al. The gut microbiota of laying hens and its manipulation with prebiotics and probiotics to enhance gut health and food safety. Appl Environ Microbiol 2020; 86: e00600-e00620
• 50 Janmohammadi P, Nourmohammadi Z, Fazelian S. et al. Does infant formula containing synbiotics support adequate growth in infants? A meta-analysis and systematic review of randomized controlled trials. Crit Rev Food Sci Nutr 2023; 63: 707-718
• 51 Joshi DC, Joshi N, Kumar A. et al. Recent advances in molecular pathways and therapeutic implications for peptic ulcer management: a comprehensive review. Horm Metab Res 2024; 56: 615-624
• 52 Hayes MT. Parkinson’s disease and Parkinsonism. Am J Med 2019; 132: 802-807
• 53 Hu Q, Wang G. Mitochondrial dysfunction in Parkinson’s disease. Transl Neurodegen 2016; 5: 1-8
• 54 Sampson TR, Challis C, Jain N. et al. A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. ELife 2020; 9: e-53111
• 55 Shandilya S, Kumar S, Kumar Jha N. et al. Interplay of gut microbiota and oxidative stress: perspective on neurodegeneration and neuroprotection. J Adv Res 2022; 38: 223
• 56 Uematsu M, Nakamura A, Ebashi M. et al. Brainstem tau pathology in Alzheimer’s disease is characterized by increase of three repeat tau and independent of amyloid β. Acta Neuropathol Commun 2012; 6: 1
• 57 Joshi DC, Joshi N, Sethiya NK. et al. Nanotechnology: a nanotherapeutics approach to counteracting brain infection. In: Elsevier eBooks. 2024: 281-310
• 58 Joshi DC, Joshi N, Kumar A. et al. Recent advances in molecular pathways and therapeutic Implications for peptic ulcer Management: a comprehensive review. Horm Metab Res 2024; 56: 615-624
• 59 Joshi DC, Joshi N, Harshita et al. To evaluate preliminary pharmacological screening of plant extract of ficus auriculata lour for anti-ulcer activity. J Adv Med Med Res. 2022: 206-213